Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
As of close of business last night, Viridian Therapeutics Inc’s stock clocked out at $21.00, down -2.55% from its previous closing price of $21.55. In other words, the price has decreased by -$2.55 from its previous closing price. On the day, 0.86 million shares were traded. VRDN stock price reached its highest trading level at $21.66 during the session, while it also had its lowest trading level at $20.76.
Ratios:
To gain a deeper understanding of VRDN’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 18.55 and its Current Ratio is at 18.55. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.03.
On September 11, 2024, Needham reiterated its Buy rating and also lowered its target price recommendation from $30 to $38.
On June 11, 2024, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $29.Wolfe Research initiated its Outperform rating on June 11, 2024, with a $29 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 27 ’24 when Beetham Thomas W. bought 5,000 shares for $23.41 per share. The transaction valued at 117,050 led to the insider holds 6,000 shares of the business.
Mahoney Stephen F. bought 21,400 shares of VRDN for $499,262 on Sep 27 ’24. The President and CEO now owns 21,400 shares after completing the transaction at $23.33 per share. On Sep 13 ’24, another insider, Fairmount Funds Management LLC, who serves as the Director of the company, bought 1,600,000 shares for $18.75 each. As a result, the insider paid 30,000,000 and bolstered with 3,445,813 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRDN now has a Market Capitalization of 1663466752 and an Enterprise Value of 1122386688. For the stock, the TTM Price-to-Sale (P/S) ratio is 5463.74 while its Price-to-Book (P/B) ratio in mrq is 3.21. Its current Enterprise Value per Revenue stands at 3716.512 whereas that against EBITDA is -3.973.
Stock Price History:
Over the past 52 weeks, VRDN has reached a high of $27.20, while it has fallen to a 52-week low of $11.40. The 50-Day Moving Average of the stock is -7.51%, while the 200-Day Moving Average is calculated to be 21.58%.
Shares Statistics:
It appears that VRDN traded 1.55M shares on average per day over the past three months and 1095270 shares per day over the past ten days. A total of 79.18M shares are outstanding, with a floating share count of 70.14M. Insiders hold about 11.45% of the company’s shares, while institutions hold 98.95% stake in the company. Shares short for VRDN as of 1731628800 were 9097352 with a Short Ratio of 5.88, compared to 1728950400 on 9791768. Therefore, it implies a Short% of Shares Outstanding of 9097352 and a Short% of Float of 13.04.
